Everolimus in kidney transplantation

References

• Laupacis A, Keown P, Pus N, et al. A study of the quality of life and cost-utility of renal transplantation. Kidney Int. 1996;50(1):235–242.
   PubMed Web of Science ®Google Scholar
• Wolfe RA, Ashby VB, Milford EL, et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med. 1999;341(23): 1725–1730.
   PubMed Web of Science ®Google Scholar
• Chan L, Gaston R, Hariharan S. Evolution of immunosuppression and continued importance of acute rejection in renal transplantation. Am J Kidney Dis. 2001;38(6 Suppl 6):S2–S9.
   Web of Science ®Google Scholar
• 2009 Annual Report of the US Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients: Transplant Data 1999–2008. Rockville, MD: US Department of Health and Human Services, Health Resources and Services Administration, Healthcare Systems Bureau, Division of Transplantation; 2009.
   Google Scholar
• Pascual M, Theruvath T, Kawai T, Tolkoff-Rubin N, Cosimi AB. Strategies to improve long-term outcomes after renal transplantation. N Engl J Med. 2002;346(8):580–590.
   PubMed Web of Science ®Google Scholar
• Lamb KE, Lodhi S, Meier-Kriesche HU. Long-term renal allograft survival in the United States: A critical reappraisal. Am J Transplant. 2011;11(3):450–462.
   PubMed Web of Science ®Google Scholar
• Meier-Kriesche HU, Schold JD, Srinivas TR, Kaplan B. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant. 2004;4(3):378–383.
   PubMed Web of Science ®Google Scholar
• Oberbauer R, Segoloni G, Campistol JM, et al. Early cyclosporine withdrawal from a sirolimus-based regimen results in better renal allograft survival and renal function at 48 months after transplantation. Transpl Int. 2005;18(1):22–28.
   PubMed Web of Science ®Google Scholar
• Lebranchu Y, Thierry A, Toupance O, et al. Efficacy on renal function of early conversion from cyclosporine to sirolimus 3 months after renal transplantation: Concept study. Am J Transplant. 2009;9(5): 1115–1123.
   PubMed Web of Science ®Google Scholar
• Schena FP, Pascoe MD, Alberu J, et al. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation. 2009;87(2):233–242.
   PubMed Web of Science ®Google Scholar
• Ekberg H, Tedesco-Silva H, Demirbas A, et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med. 2007;357(25):2562–2575.
   PubMed Web of Science ®Google Scholar
• Schuler W, Sedrani R, Cottens S, et al. SDZ RAD, a new rapamycin derivative: Pharmacological properties in vitro and in vivo. Transplantation. 1997;64(1):36–42.
   PubMed Web of Science ®Google Scholar
• Crowe A, Bruelisauer A, Duerr L, Guntz P, Lemaire M. Absorption and intestinal metabolism of SDZ-RAD and rapamycin in rats. Drug Metab Dispos. 1999;27(5):627–632.
   PubMed Web of Science ®Google Scholar
• Kahan BD, Kaplan B, Lorber MI, Winkler M, Cambon N, Boger RS. RAD in de novo renal transplantation: Comparison of three doses on the incidence and severity of acute rejection. Transplantation. 2001; 71(10):1400–1406.
   PubMed Web of Science ®Google Scholar
• Schuurman HJ, Cottens S, Fuchs S, et al. SDZ RAD, a new rapamycin derivative: Synergism with cyclosporine. Transplantation. 1997;64(1):32–35.
   PubMed Web of Science ®Google Scholar
• Zoncu R, Efeyan A, Sabatini DM. mTOR: From growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol. 2011;12(1): 21–35.
   PubMed Web of Science ®Google Scholar
• Terada N, Lucas JJ, Szepesi A, Franklin RA, Takase K, Gelfand EW. Rapamycin inhibits the phosphorylation of p70 S6 kinase in IL-2 and mitogen-activated human T cells. Biochem Biophys Res Commun. 1992;186(3):1315–1321.
   Web of Science ®Google Scholar
• Kuo CJ, Chung J, Fiorentino DF, Flanagan WM, Blenis J, Crabtree GR. Rapamycin selectively inhibits interleukin-2 activation of p70 S6 kinase. Nature. 1992;358(6381):70–73.
   Web of Science ®Google Scholar
• Sedrani R, Cottens S, Kallen J, Schuler W. Chemical modification of rapamycin: The discovery of SDZ RAD. Transplant Proc. 1998; 30(5):2192–2194.
   PubMed Web of Science ®Google Scholar
• Dumont FJ. Everolimus. Novartis. Curr Opin Investig Drugs. 2001; 2(9):1220–1234.
   Google Scholar
• Crowe A, Lemaire M. In vitro and in situ absorption of SDZ-RAD using a human intestinal cell line (Caco-2) and a single pass perfusion model in rats: Comparison with rapamycin. Pharm Res. 1998;15(11): 1666–1672.
   PubMed Web of Science ®Google Scholar
• Kirchner GI, Meier-Wiedenbach I, Manns MP. Clinical pharmacokinetics of everolimus. Clin Pharmacokinet. 2004;43(2):83–95.
   PubMed Web of Science ®Google Scholar
• Kovarik JM, Hartmann S, Figueiredo J, Rouilly M, Port A, Rordorf C. Effect of rifampin on apparent clearance of everolimus. Ann Pharmacother. 2002;36(6):981–985.
   PubMed Web of Science ®Google Scholar
• Kovarik JM, Kahan BD, Kaplan B, et al. Longitudinal assessment of everolimus in de novo renal transplant recipients over the first posttransplant year: Pharmacokinetics, exposure-response relationships, and influence on cyclosporine. Clin Pharmacol Ther. 2001;69(1): 48–56.
   Web of Science ®Google Scholar
• Jacobsen W, Serkova N, Hausen B, Morris RE, Benet LZ, Christians U. Comparison of the in vitro metabolism of the macrolide immunosuppressants sirolimus and RAD. Transplant Proc. 2001;33(1–2):514–515.
   PubMed Web of Science ®Google Scholar
• Filler G, Bendrick-Peart J, Christians U. Pharmacokinetics of mycophenolate mofetil and sirolimus in children. Ther Drug Monit. 2008;30(2):138–142.
   PubMed Web of Science ®Google Scholar
• Filler G, Bendrick-Peart J, Strom T, Zhang YL, Johnson G, Christians U. Characterization of sirolimus metabolites in pediatric solid organ transplant recipients. Pediatr Transplant. 2009;13(1):44–53.
   Web of Science ®Google Scholar
• Zollinger M, Sayer C, Dannecker R, Schuler W, Sedrani R. The macrolide everolimus forms an unusual metabolite in animals and humans: Identification of a phosphocholine ester. Drug Metab Dispos. 2008;36(8):1457–1460.
   Web of Science ®Google Scholar
• Christians U, Sattler M, Schiebel HM, et al. Isolation of two immunosuppressive metabolites after in vitro metabolism of rapamycin. Drug Metab Dispos. 1992;20(2):186–191.
   PubMed Web of Science ®Google Scholar
• Kuhn B, Jacobsen W, Christians U, Benet LZ, Kollman PA. Metabolism of sirolimus and its derivative everolimus by cytochrome P450 3A4: Insights from docking, molecular dynamics, and quantum chemical calculations. J Med Chem. 2001;44(12):2027–2034.
   PubMed Web of Science ®Google Scholar
• Kovarik JM, Hsu CH, McMahon L, Berthier S, Rordorf C. Population pharmacokinetics of everolimus in de novo renal transplant patients: Impact of ethnicity and comedications. Clin Pharmacol Ther. 2001; 70(3):247–254.
   PubMed Web of Science ®Google Scholar
• Christians U, Schmitz V, Haschke M. Functional interactions between P-glycoprotein and CYP3A in drug metabolism. Expert Opin Drug Metab Toxicol. 2005;1(4):641–654.
   PubMedGoogle Scholar
• Everolimus prescribing information. Available at: http://www.pharma.us.novartis.com/product/pi/pdf/zortress.pdf. 2010. Accessed on March 31, 2011.
   Google Scholar
• Kovarik JM, Sabia HD, Figueiredo J, et al. Influence of hepatic impairment on everolimus pharmacokinetics: Implications for dose adjustment. Clin Pharmacol Ther. 2001;70(5):425–430.
   PubMed Web of Science ®Google Scholar
• Benet LZ. Relevance of pharmacokinetics in narrow therapeutic index drugs. Transplant Proc. 1999;31(3):1642–1644.
   Web of Science ®Google Scholar
• Anglicheau D, Legendre C, Beaune P, Thervet E. Cytochrome P450 3A polymorphisms and immunosuppressive drugs: An update. Pharmacogenomics. 2007;8(7):835–849.
   PubMed Web of Science ®Google Scholar
• Kovarik JM, Kaplan B, Silva HT, et al. Pharmacokinetics of an everoli-mus-cyclosporine immunosuppressive regimen over the first 6 months after kidney transplantation. Am J Transplant. 2003;3(5):606–613.
   PubMed Web of Science ®Google Scholar
• Kovarik JM, Kaplan B, Tedesco Silva H, et al. Exposure-response relationships for everolimus in de novo kidney transplantation: Defining a therapeutic range. Transplantation. 2002;73(6):920–925.
   PubMed Web of Science ®Google Scholar
• Lorber MI, Ponticelli C, Whelchel J, et al. Therapeutic drug monitoring for everolimus in kidney transplantation using 12-month exposure, efficacy, and safety data. Clin Transplant. 2005;19(2):145–152.
   Web of Science ®Google Scholar
• Kaplan B, Meier-Kriesche HU, Napoli KL, Kahan BD. The effects of relative timing of sirolimus and cyclosporine microemulsion formulation coadministration on the pharmacokinetics of each agent. Clin Pharmacol Ther. 1998;63(1):48–53.
   PubMed Web of Science ®Google Scholar
• Kovarik JM, Kalbag J, Figueiredo J, Rouilly M, Frazier OL, Rordorf C. Differential influence of two cyclosporine formulations on everolimus pharmacokinetics: A clinically relevant pharmacokinetic interaction. J Clin Pharmacol. 2002;42(1):95–99.
   PubMed Web of Science ®Google Scholar
• Budde K, Lehne G, Winkler M, et al. Influence of everolimus on steady-state pharmacokinetics of cyclosporine in maintenance renal transplant patients. J Clin Pharmacol. 2005;45(7):781–791.
   Web of Science ®Google Scholar
• McAlister VC, Mahalati K, Peltekian KM, Fraser A, MacDonald AS. A clinical pharmacokinetic study of tacrolimus and sirolimus combination immunosuppression comparing simultaneous to separated administration. Ther Drug Monit. 2002;24(3):346–350.
   Web of Science ®Google Scholar
• Kovarik JM, Curtis JJ, Hricik DE, Pescovitz MD, Scantlebury V, Vasquez A. Differential pharmacokinetic interaction of tacrolimus and cyclosporine on everolimus. Transplant Proc. 2006;38(10):3456–3458.
   Web of Science ®Google Scholar
• Chan L, Hartmann E, Cibrik D, Cooper M, Shaw LM. Optimal everolimus concentration is associated with risk reduction for acute rejection in de novo renal transplant recipients. Transplantation. 2010;90(1):31–37.
   Web of Science ®Google Scholar
• Chan L, Greenstein S, Hardy MA, et al. Multicenter, randomized study of the use of everolimus with tacrolimus after renal transplantation demonstrates its effectiveness. Transplantation. 2008;85(6):821–826.
   Web of Science ®Google Scholar
• Kovarik JM, Hartmann S, Figueiredo J, et al. Effect of food on everolimus absorption: Quantification in healthy subjects and a confirmatory screening in patients with renal transplants. Pharmacotherapy. 2002;22(2):154–159.
   PubMed Web of Science ®Google Scholar
• Lown KS, Bailey DG, Fontana RJ, et al. Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression. J Clin Invest. 1997;99(10):2545–2553.
   PubMed Web of Science ®Google Scholar
• Mannel M. Drug interactions with St John’s wort: Mechanisms and clinical implications. Drug Saf. 2004;27(11):773–797.
   PubMed Web of Science ®Google Scholar
• Morgan ET. Regulation of cytochromes P450 during inflammation and infection. Drug Metab Rev. 1997;29(4):1129–1188.
   PubMed Web of Science ®Google Scholar
• Iber H, Sewer MB, Barclay TB, Mitchell SR, Li T, Morgan ET. Modulation of drug metabolism in infectious and inflammatory diseases. Drug Metab Rev. 1999;31(1):29–41.
   PubMed Web of Science ®Google Scholar
• Sukhai M, Piquette-Miller M. Regulation of the multidrug resistance genes by stress signals. J Pharm Pharm Sci. 2000;3(2):268–280.
   PubMed Web of Science ®Google Scholar
• Trotter JF, Osborne JC, Heller M, Christians U. Effect of hepatitis C infection on tacrolimus doses and blood levels in liver transplantation recipients. Aliment Pharmacol Ther. 2005;22(1):37^4.
   Web of Science ®Google Scholar
• Salm P, Warnholtz C, Boyd J, Arabshahi L, Marbach P, Taylor PJ. Evaluation of a fluorescent polarization immunoassay for whole blood everolimus determination using samples from renal transplant recipients. Clin Biochem. 2006;39(7):732–738.
   Web of Science ®Google Scholar
• Strom T, Haschke M, Boyd J, et al. Crossreactivity of isolated everolimus metabolites with the Innofluor Certican immunoassay for therapeutic drug monitoring of everolimus. Ther Drug Monit. 2007; 29(6):743–749.
   Web of Science ®Google Scholar
• Korecka M, Shaw LM. Review of the newest HPLC methods with mass spectrometry detection for determination of immunosuppressive drugs in clinical practice. Ann Transplant. 2009;14(2):61–72.
   PubMed Web of Science ®Google Scholar
• United Kingdom National External Quality Assessment Service. Available at: http://www.ukneqas.org.uk/content/Pageserver.asp. Accessed on March 31, 2011.
   Google Scholar
• Hausen B, Boeke K, Berry GJ, Segarra IT, Christians U, Morris RE. Suppression of acute rejection in allogeneic rat lung transplantation: A study of the efficacy and pharmacokinetics of rapamycin derivative (SDZ RAD) used alone and in combination with a microemulsion formulation of cyclosporine. J Heart Lung Transplant. 1999;18(2):150–159.
   Web of Science ®Google Scholar
• Cole OJ, Shehata M, Rigg KM. Effect of SDZ RAD on transplant arteriosclerosis in the rat aortic model. Transplant Proc. 1998; 30(5):2200–2203.
   Web of Science ®Google Scholar
• Schuurman HJ, Ringers J, Schuler W, Slingerland W, Jonker M. Oral efficacy of the macrolide immunosuppressant SDZ RAD and of cyclosporine microemulsion in cynomolgus monkey kidney allotransplantation. Transplantation. 2000;69(5):737–742.
   Web of Science ®Google Scholar
• Viklicky O, Zou H, Muller V, Lacha J, Szabo A, Heemann U. SDZ-RAD prevents manifestation of chronic rejection in rat renal allografts. Transplantation. 2000;69(4):497–502.
   Web of Science ®Google Scholar
• Schuurman HJ, Pally C, Weckbecker G, Schuler W, Bruns C. SDZ RAD inhibits cold ischemia-induced vascular remodeling. Transplant Proc. 1999;31(1–2):1024–1025.
   Web of Science ®Google Scholar
• Serkova N, Christians U. Transplantation: Toxicokinetics and mechanisms of toxicity of cyclosporine and macrolides. Curr Opin Investig Drugs. 2003;4(11):1287–1296.
   PubMedGoogle Scholar
• Vitko S, Margreiter R, Weimar W, et al. Everolimus (Certican) 12-month safety and efficacy versus mycophenolate mofetil in de novo renal transplant recipients. Transplantation. 2004;78(10):1532–1540.
   PubMed Web of Science ®Google Scholar
• Vitko S, Margreiter R, Weimar W, et al. Three-year efficacy and safety results from a study of everolimus versus mycophenolate mofetil in de novo renal transplant patients. Am J Transplant. 2005;5(10):2521–2530.
   PubMed Web of Science ®Google Scholar
• Lorber MI, Mulgaonkar S, Butt KM, et al. Everolimus versus myco-phenolate mofetil in the prevention of rejection in de novo renal transplant recipients: A 3-year randomized, multicenter, phase III study. Transplantation. 2005;80(2):244–252.
   PubMed Web of Science ®Google Scholar
• Podder H, Stepkowski SM, Napoli KL, et al. Pharmacokinetic interactions augment toxicities of sirolimus/cyclosporine combinations. J Am Soc Nephrol. 2001;12(5):1059–1071.
   PubMed Web of Science ®Google Scholar
• Nashan B, Curtis J, Ponticelli C, Mourad G, Jaffe J, Haas T. Everolimus and reduced-exposure cyclosporine in de novo renal-transplant recipients: A three-year phase II, randomized, multicenter, open-label study. Transplantation. 2004;78(9):1332–1340.
   PubMed Web of Science ®Google Scholar
• Vitko S, Tedesco H, Eris J, et al. Everolimus with optimized cyclosporine dosing in renal transplant recipients: 6-month safety and efficacy results of two randomized studies. Am J Transplant. 2004;4(4):626–635.
   PubMed Web of Science ®Google Scholar
• Tedesco-Silva H Jr, Vitko S, Pascual J, et al. 12-month safety and efficacy of everolimus with reduced exposure cyclosporine in de novo renal transplant recipients. Transpl Int. 2007;20(1):27–36.
   PubMed Web of Science ®Google Scholar
• Tedesco Silva H Jr, Cibrik D, Johnston T, et al. Everolimus plus reduced-exposure CsA versus mycophenolic acid plus standard-exposure CsA in renal-transplant recipients. Am J Transplant. 2010;10(6):1401–1413.
   PubMed Web of Science ®Google Scholar
• Budde K, Becker T, Arns W, et al. Everolimus-based, calcineurin-inhib-itor-free regimen in recipients of de-novo kidney transplants: An open-label, randomised, controlled trial. Lancet. 2011;377(9768):837–847.
   PubMed Web of Science ®Google Scholar
• Wu O, Levy AR, Briggs A, Lewis G, Jardine A. Acute rejection and chronic nephropathy: A systematic review of the literature. Transplantation. 2009;87(9):1330–1339.
   Web of Science ®Google Scholar
• Sijpkens YW Doxiadis, II, Mallat MJ, et al. Early versus late acute rejection episodes in renal transplantation. Transplantation. 2003;75(2):204–208.
   PubMed Web of Science ®Google Scholar
• Mendez R, Gonwa T, Yang HC, Weinstein S, Jensik S, Steinberg S. A prospective, randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: Results at 1 year. Transplantation. 2005;80(3):303–309.
   Web of Science ®Google Scholar
• Ciancio G, Burke GW, Gaynor JJ, et al. A randomized long-term trial of tacrolimus/sirolimus versus tacrolimums/mycophenolate versus cyclosporine/sirolimus in renal transplantation: Three-year analysis. Transplantation. 2006;81(6):845–852.
   Web of Science ®Google Scholar
• Vitko S, Wlodarczyk Z, Kyllonen L, et al. Tacrolimus combined with two different dosages of sirolimus in kidney transplantation: Results of a multicenter study. Am J Transplant. 2006;6(3):531–538.
   Web of Science ®Google Scholar
• Meier-Kriesche HU, Schold JD, Srinivas TR, Howard RJ, Fujita S, Kaplan B. Sirolimus in combination with tacrolimus is associated with worse renal allograft survival compared with mycophenolate mofetil combined with tacrolimus. Am J Transplant. 2005;5(9):2273–2280.
   Web of Science ®Google Scholar
• Gralla J, Wiseman AC. Tacrolimus/sirolimus versus tacrolimus/mycophenolate in kidney transplantation: Improved 3-year graft and patient survival in recent era. Transplantation. 2009;87(11):1712–1719.
   Web of Science ®Google Scholar
• Rostaing L, Kamar N. mTOR inhibitor/proliferation signal inhibitors: Entering or leaving the field? J Nephrol. 2010;23(2):133–142.
   Web of Science ®Google Scholar
• Kasiske BL, de Mattos A, Flechner SM, et al. Mammalian target of rapamycin inhibitor dyslipidemia in kidney transplant recipients. Am J Transplant. 2008;8(7):1384–1392.
   PubMed Web of Science ®Google Scholar
• Augustine JJ, Knauss TC, Schulak JA, Bodziak KA, Siegel C, Hricik DE. Comparative effects of sirolimus and mycophenolate mofetil on erythropoiesis in kidney transplant patients. Am J Transplant. 2004;4(12):2001–2006.
   PubMed Web of Science ®Google Scholar
• Augustine JJ, Rodriguez V, Padiyar A, Bodziak KA, Schulak JA, Hricik DE. Reduction in erythropoietin resistance after conversion from sirolimus to enteric coated mycophenolate sodium. Transplantation. 2008;86(4):548–553.
   Web of Science ®Google Scholar
• Maiorano A, Stallone G, Schena A, et al. Sirolimus interferes with iron homeostasis in renal transplant recipients. Transplantation. 2006;82(7):908–912.
   Web of Science ®Google Scholar
• Sanchez Fructuoso A, Calvo N, Moreno MA, Giorgi M, Barrientos A. Study of anemia after late introduction of everolimus in the immunosuppressive treatment of renal transplant patients. Transplant Proc. 2007;39(7):2242–2244.
   Web of Science ®Google Scholar
• Letavernier E, Legendre C. mToR inhibitors-induced proteinuria: Mechanisms, significance, and management. Transplant Rev (Orlando). 2008;22(2):125–130.
   Google Scholar
• Franco AF, Martini D, Abensur H, Noronha IL. Proteinuria in transplant patients associated with sirolimus. Transplant Proc. 2007;39(2):449^52.
   Web of Science ®Google Scholar
• Ruiz JC, Campistol JM, Sanchez-Fructuoso A, et al. Early sirolimus use with cyclosporine elimination does not induce progressive proteinuria. Transplant Proc. 2007;39(7):2151–2152.
   Web of Science ®Google Scholar
• Straathof-Galema L, Wetzels JF, Dijkman HB, Steenbergen EJ, Hilbrands LB. Sirolimus-associated heavy proteinuria in a renal transplant recipient: Evidence for a tubular mechanism. Am J Transplant. 2006;6(2):429–433.
   PubMed Web of Science ®Google Scholar
• Van den Akker JM, Wetzels JF, Hoitsma AJ. Proteinuria following conversion from azathioprine to sirolimus in renal transplant recipients. Kidney Int. 2006;70(7):1355–1357.
   PubMed Web of Science ®Google Scholar
• Biancone L, Bussolati B, Mazzucco G, et al. Loss of nephrin expression in glomeruli of kidney-transplanted patients under m-TOR inhibitor therapy. Am J Transplant. 2010;10(10):2270–2278.
   Web of Science ®Google Scholar
• McTaggart RA, Tomlanovich S, Bostrom A, Roberts JP, Feng S. Comparison of outcomes after delayed graft function: Sirolimus-based versus other calcineurin-inhibitor sparing induction immunosuppression regimens. Transplantation. 2004;78(3):475–480.
   PubMed Web of Science ®Google Scholar
• Durrbach A, Rostaing L, Tricot L, et al. Prospective comparison of the use of sirolimus and cyclosporine in recipients of a kidney from an expanded criteria donor. Transplantation. 2008;85(3):486–490.
   Web of Science ®Google Scholar
• Stallone G, Di Paolo S, Schena A, et al. Addition of sirolimus to cyclosporine delays the recovery from delayed graft function but does not affect 1-year graft function. J Am Soc Nephrol. 2004;15(1): 228–233.
   Web of Science ®Google Scholar
• Simon JF, Swanson SJ, Agodoa LY, Cruess DF, Bohen EM, Abbott KC. Induction sirolimus and delayed graft function after deceased donor kidney transplantation in the United States. Am J Nephrol. 2004;24(4):393–401.
   Web of Science ®Google Scholar
• Dantal J, Berthoux F, Moal MC, et al. Efficacy and safety of de novo or early everolimus with low cyclosporine in deceased-donor kidney transplant recipients at specified risk of delayed graft function: 12-month results of a randomized, multicenter trial. Transpl Int. 2010;23(11):1084–1093.
   PubMed Web of Science ®Google Scholar
• Langer RM, Kahan BD. Incidence, therapy, and consequences of lymphocele after sirolimus-cyclosporine-prednisone immunosuppression in renal transplant recipients. Transplantation. 2002;74(6): 804–808.
   PubMed Web of Science ®Google Scholar
• Valente JF, Hricik D, Weigel K, et al. Comparison of sirolimus versus mycophenolate mofetil on surgical complications and wound healing in adult kidney transplantation. Am J Transplant. 2003; 3(9):1128–1134.
   Web of Science ®Google Scholar
• Troppmann C, Pierce JL, Gandhi MM, Gallay BJ, McVicar JP, Perez RV. Higher surgical wound complication rates with sirolimus immunosuppression after kidney transplantation: A matched-pair pilot study. Transplantation. 2003;76(2):426–429.
   PubMed Web of Science ®Google Scholar
• Dean PG, Lund WJ, Larson TS, et al. Wound-healing complications after kidney transplantation: A prospective, randomized comparison of sirolimus and tacrolimus. Transplantation. 2004;77(10):1555–1561.
   PubMed Web of Science ®Google Scholar
• Penn I. Cancers complicating organ transplantation. N Engl J Med. 1990;323(25):1767–1769.
   PubMed Web of Science ®Google Scholar
• Agraharkar ML, Cinclair RD, Kuo YF, Daller JA, Shahinian VB. Risk of malignancy with long-term immunosuppression in renal transplant recipients. Kidney Int. 2004;66(1):383–389.
   PubMed Web of Science ®Google Scholar
• Morath C, Mueller M, Goldschmidt H, Schwenger V, Opelz G, Zeier M. Malignancy in renal transplantation. J Am Soc Nephrol. 2004;15(6):1582–1588.
   Web of Science ®Google Scholar
• Kasiske BL, Snyder JJ, Gilbertson DT, Wang C. Cancer after kidney transplantation in the United States. Am J Transplant. 2004;4(6): 905–913.
   PubMed Web of Science ®Google Scholar
• Vignot S, Faivre S, Aguirre D, Raymond E. mTOR-targeted therapy of cancer with rapamycin derivatives. Ann Oncol. 2005; 16(4): 525–537.
   PubMed Web of Science ®Google Scholar
• Campistol JM, Eris J, Oberbauer R, et al. Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation. J Am Soc Nephrol. 2006;17(2):581–589.
   PubMed Web of Science ®Google Scholar
• Krueger DA, Care MM, Holland K, et al. Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. N Engl J Med. 2010; 363(19):1801–1811.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: A double-blind, randomised, placebocontrolled phase III trial. Lancet. 2008;372(9637):449–456.
   PubMed Web of Science ®Google Scholar
• Krams SM, Martinez OM. Epstein-Barr virus, rapamycin, and host immune responses. Curr Opin Organ Transplant. 2008;13(6): 563–568.
   Web of Science ®Google Scholar
• Haydar AA, Denton M, West A, Rees J, Goldsmith DJ. Sirolimus-induced pneumonitis: Three cases and a review of the literature. Am J Transplant. 2004;4(1):137–139.
   Web of Science ®Google Scholar
• Champion L, Stern M, Israel-Biet D, et al. Brief communication: Sirolimus-associated pneumonitis: 24 cases in renal transplant recipients. Ann Intern Med. 2006;144(7):505–509.
   PubMed Web of Science ®Google Scholar
• Langer RM, Van Buren CT, Katz SM, Kahan BD. De novo hemolytic uremic syndrome after kidney transplantation in patients treated with cyclosporine-sirolimus combination. Transplantation. 2002;73(5):756–760.
   PubMed Web of Science ®Google Scholar
• Fortin MC, Raymond MA, Madore F, et al. Increased risk of thrombotic microangiopathy in patients receiving a cyclosporin-sirolimus combination. Am J Transplant. 2004;4(6):946–952.
   Web of Science ®Google Scholar
• Crew RJ, Radhakrishnan J, Cohen DJ, et al. De novo thrombotic microangiopathy following treatment with sirolimus: Report of two cases. Nephrol Dial Transplant. 2005;20(1):203–209.
   Web of Science ®Google Scholar
• Otton J, Hayward CS, Keogh AM, Glanville AR, Macdonald PS. Everolimus-associated pneumonitis in 3 heart transplant recipients. J Heart Lung Transplant. 2009;28(1):104–106.
   Web of Science ®Google Scholar
• Mahe E, Morelon E, Lechaton S, et al. Cutaneous adverse events in renal transplant recipients receiving sirolimus-based therapy. Transplantation. 2005;79(4):476^82.
   Web of Science ®Google Scholar
• Desai N, Heenan S, Mortimer PS. Sirolimus-associated lymphoedema: Eight new cases and a proposed mechanism. Br J Dermatol. 2009; 160(6):1322–1326.
   PubMed Web of Science ®Google Scholar
• Strom T, Haschke M, Zhang YL, et al. Identification of everolimus metabolite patterns in trough blood samples of kidney transplant patients. Ther Drug Monit. 2007;29(5):592–599.
   PubMed Web of Science ®Google Scholar